Farnesyltransferase inhibition overcomes the adaptive resistance to osimertinib in EGFR-mutant NSCLC
S. Figarol, C. Delahaye, R. Gence, R. Asslan, S. Pagano, C. Tardy, J. Colinge, J.-P. Villemin, A. Maraver, I. Ferrer, L. Paz-Ares, I. Lajoie-Mazenc, E. Clermont, A. Casanova, A. Pradines, , G. Favre
This study identifies early escapers as a rare cell population resistant to EGFR-TKi and shows that tipifarnib overcomes this resistance by targeting Rho/ROCK pathway and preventing relapse.
bioRxiv · Apr 1, 2022 · PreprintCancer Biology